|
Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (PDF, 277Kb)
|
|
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox–Gastaut syndrome in people aged 2 years and older (PP203), February 2021 (PDF, 545Kb)
|
|
Circumcision for Children, Commissioning Policy, (CP34). March 2019 (PDF, 344Kb)
|
|
CP186 Cleft Lip and or Palate including Non-Cleft Velopharyngeal Dysfunction All Ages (PDF, 680Kb)
|
|
Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
|
|
Nusinersen for treating spinal muscular atrophy, Policy Position Statement, (PP191). January 2022 (PDF, 399Kb)
|
|
CP163 Paediatric Endocrinology (PDF, 283Kb)
|
|
Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (PDF, 487Kb)
|
|
Paediatric Nephrology Service Specification CP169 (March 2021) (PDF, 443Kb)
|
|
Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (PDF, 361Kb)
|
|
South Wales Neonatal Transport Operational Delivery Network, (CP244) October 2022 (PDF, 303Kb)
|
|
Specialised Paediatric Rheumatology Service Specification (CP172). November 2021 (PDF, 475Kb)
|
|
Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (PDF, 311Kb)
|